PSP
VRTX icon

Principal Street Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Principal Street Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$887K Buy
1,987
+2
+0.1% +$933 0.14% 85
2025
Q4 		$900K Sell
1,985
-360
-15% -$155K 0.15% 83
2025
Q3 		$918K Sell
2,345
-1,526
-39% -$638K 0.15% 85
2025
Q2 		$1.72M Buy
3,871
+1,535
+66% +$707K 0.17% 83
2025
Q1 		$1.13M Buy
2,336
+78
+3% +$36.3K 0.21% 69
2024
Q4 		$909K Sell
2,258
-752
-25% -$349K 0.18% 74
2024
Q3 		$1.41M Buy
3,010
+629
+26% +$302K 0.23% 71
2024
Q2 		$1.12M Sell
2,381
-29
-1% -$12.6K 0.2% 69
2024
Q1 		$1.01M Buy
2,410
+177
+8% +$74.8K 0.19% 71
2023
Q4 		$909K Sell
2,233
-102
-4% -$37.7K 0.22% 73
2023
Q3 		$812K Sell
2,335
-117
-5% -$40.9K 0.16% 97
2023
Q2 		$863K Sell
2,452
-28
-1% -$9.43K 0.21% 77
2023
Q1 		$781K Sell
2,480
-974
-28% -$292K 0.2% 77
2022
Q4 		$997K Sell
3,454
-291
-8% -$88.7K 0.25% 66
2022
Q3 		$1.08M Buy
3,745
+153
+4% +$44K 0.29% 64
2022
Q2 		$1.01M Sell
3,592
-479
-12% -$128K 0.26% 66
2022
Q1 		$1.06M Sell
4,071
-351
-8% -$83.3K 0.24% 71
2021
Q4 		$971K Buy
4,422
+1,603
+57% +$312K 0.23% 75
2021
Q3 		$512K Sell
2,819
-1,463
-34% -$286K 0.14% 117
2021
Q2 		$864K Sell
4,282
-4,783
-53% -$1M 0.23% 87
2021
Q1 		$1.95M Buy
9,065
+4,631
+104% +$1.02M 0.25% 77
2020
Q4 		$1.05M Buy
4,434
+229
+5% +$52.5K 0.32% 71
2020
Q3 		$1.14M Sell
4,205
-150
-3% -$41.4K 0.4% 67
2020
Q2 		$1.26M Buy
4,355
+134
+3% +$36.3K 0.47% 57
2020
Q1 		$1M Sell
4,221
-1,005
-19% -$231K 0.42% 49
2019
Q4 		$1.14M Sell
5,226
-1,691
-24% -$342K 0.25% 68
2019
Q3 		$1.16M Buy
6,917
+2,928
+73% +$518K 0.29% 61
2019
Q2 		$732K Buy
3,989
+434
+12% +$75.9K 0.4% 74
2019
Q1 		$654K Buy
+3,555
New +$657K 0.28% 52

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Principal Street Partners's VRTX Position: Q1 2026 in Review

Principal Street Partners increased its Vertex Pharmaceuticals (VRTX) stake by 0.1% in Q1 2026, buying an estimated $933 and bringing the position to 1,987 shares worth $887K. The position accounts for 0.14% of the portfolio, ranked #85.

Principal Street Partners first reported a position in VRTX in Q1 2019 and has held it in 29 quarters since. The position peaked at $1.95M in Q1 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Principal Street Partners held 1,987 shares of Vertex Pharmaceuticals worth $887K as of Q1 2026.
  • Principal Street Partners bought 2 Vertex Pharmaceuticals shares in Q1 2026, an estimated $933.
  • Vertex Pharmaceuticals made up 0.14% of Principal Street Partners's portfolio in Q1 2026, its #85 holding.
  • Principal Street Partners first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 29 quarters since.
  • Principal Street Partners's Vertex Pharmaceuticals position peaked at $1.95M in Q1 2021.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Principal Street Partners's 13F filing for Q1 2026, filed 15 May 2026.